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Abstract
Background: Osteopontin (OPN) is a highly phosphorylated sialoprotein and a soluble cytokine that is widely
expressed in a variety of tissues, including the brain. OPN and OPN-derived peptides have been suggested to have
potential neuroprotective effects against ischemic brain injury, but their role in preterm brain injury is unknown.
Methods: We used a hypoxia-ischemia (HI)-induced preterm brain injury model in postnatal day 5 mice. OPN and
OPN-derived peptides were given intracerebroventricularly and intranasally before HI. Brain injury was evaluated at
7 days after the insults.
Results: There was a significant increase in endogenous OPN mRNA and OPN protein in the mouse brain after the
induction of HI at postnatal day 5. Administration of full-length OPN protein and thrombin-cleaved OPN did not
affect preterm brain injury. This was demonstrated with both intracerebroventricular and intranasal administration
of OPN as well as in OPN-deficient mice. Interestingly, both N134–153 and C154–198 OPN-derived peptides increased
the severity of brain injury in this HI-induced preterm brain injury model.
Conclusions: The neuroprotective effects of OPN are age-dependent, and, in contrast to the more mature brain,
OPN-derived peptides potentiate injury in postnatal day 5 mice. Intranasal administration is an efficient way of delivering
drugs to the central nervous system (CNS) in neonatal mice and is likely to be an easy and noninvasive method of drug
delivery to the CNS in preterm infants.
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Background
Preterm brain injury, especially in combination with very
low birth weight, has become the dominant form of brain
injury in neonates. These brain injuries are associated with
impaired quality of life due to resulting disorders such as
cerebral palsy and behavioral, social, attentional and cog-
nitive deficits. Preterm brain injury is generally thought to
consist primarily of white-matter injury that is accompan-
ied by elements of gray-matter injury and is characterized
by a loss of premyelinating oligodendrocytes (pre-OLs)
and a deficiency in their development into myelinating
oligodendroglia [1]. In infants with preterm brain injury,
especially preterm infants with very low birth weight, the
abnormal growth and maturation of susceptible cell types,
particularly oligodendrocytes and neurons, are associated
with decreased cerebral and cerebellar volumes and in-
creases in cerebral ventricular size [2].
Osteopontin (OPN) is a glycoprotein with an arginine–
glycine–aspartic acid (RGD) motif that binds to the αvβ1,
αvβ3, αvβ5, αvβ6, α8β1 and α5β1 integrin receptors. It is
widely expressed in a variety of tissues, including the
brain. OPN is also highly expressed in injured tissues and
has been proposed to enhance wound healing by modulat-
ing inflammation and fibrosis and by promoting Th17 and
Th1 responses [3,4]. OPN is cleaved posttranslationally
by matrix metalloproteinases and thrombin into an N-
terminal fragment and a C-terminal fragment, and the
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length OPN, thrombin-cleaved OPN and peptides based
on sequences from the N-terminal and C-terminal sides
of the thrombin cleavage site all protect against ischemic
brain injury [6,7]. In the neonatal brain, OPN is the most
highly expressed gene in a postnatal day 9 (PND9) hypoxia-
ischemia (HI)-induced neonatal brain injury mouse model
[8], and strong OPN immunoreactivity has been seen in
axons at the periphery of the ischemic zone in both sub-
acute and chronic brain injury lesions in human newborn
infants [9]. OPN enhances endogenous brain injury repair
and protects the neonatal brain from HI-induced brain
injury in PND9 mice [10] and PND7 rats [11], both of
which are animal models that correspond to neonatal
hypoxic-ischemic encephalopathy (HIE) in near-term
human infants. All of this evidence suggests that OPN
and OPN-derived peptides might represent promising
candidates for neuroprotection. However, it is unknown
how they contribute to preterm brain injuries. Many
characteristics of rodents before PND7—such as the
maturation and development of oligodendrocytes [12]
and antigen-presenting dendritic cells in the immune
system [13] and the expression of OPN receptor αvβ1
integrin on oligodendrocytes [14]—are similar to those
seen in human brain development at preterm ages [12].
This indicates that the degree of neuroprotection medi-
ated by OPN might be very different in PND5 rodents
compared to older rodents. The aim of the present
study was to investigate the role of OPN and OPN-




C57BL/6J mice deficient in OPN (OPN
−/−; B6.129S6
(Cg)-Spp1
tm1Blh/J) and matched wild-type control mice
were purchased from The Jackson Laboratory (Bar
Harbor, ME, USA) and were bred in the animal facility
at the University of Gothenburg (Experimental Biomedi-
cine, University of Gothenburg). The mice were housed
with a 12:12-hour light–dark cycle and had free access
to a standard laboratory chow diet (B&K, Solna, Sweden)
and drinking water. All animal experiments were ap-
proved by the Animal Ethical Committee of the Univer-
sity of Gothenburg (no. 5/2013).
Hypoxia-ischemia procedure
At PND5, wild-type mice and OPN
−/− mice of both
sexes were subjected to HI insult according to a method
described previously [15-17]. Briefly, mice were anesthe-
tized with isoflurane (5.0% for induction and 1.5% to
3.0% for maintenance) in a 1:1 mixture of nitrous oxide
and oxygen. The left common carotid artery was ligated,
and the mice were returned to their cages and allowed
to recover for 1 hour. The mice were then placed in
an incubator perfused with a humidified gas mixture
(10% ± 0.01% oxygen in nitrogen) at 36°C for 70 minutes.
The combination of arterial ligation and hypoxia resulted
in injury only in the hemisphere ipsilateral to the arterial
ligation (the left hemisphere), and no injury was produced
in the contralateral hemisphere (the right hemisphere).
After HI-induced injury, the pups were returned to their




Recombinant mouse OPN (rmOPN, glycosylated) was
purchased from Sigma-Aldrich (O2260; Sigma-Aldrich, St
Louis, MO, USA) and reconstituted in phosphate-buffered
saline (PBS).
Preparation of thrombin-cleaved osteopontin
Thrombin cleavage of rmOPN was performed using a
Thrombin CleanCleave Kit (RECOMT; Sigma-Aldrich)
following the instructions from the manufacturer with
some modifications. Briefly, 50 μl of thrombin-agarose
resin was centrifuged for 5 minutes at 500 × g to pellet
the thrombin-agarose resin. The supernatant was re-
moved, and the thrombin-agarose resin was resuspended
and washed two times in 250 μl of 1× cleavage buffer,
followed by centrifugation at 500 × g for 5 minutes. The
supernatant was removed and discarded. After the
second wash, the thrombin-agarose resin was resus-
pended in 50 μl of 10× cleavage buffer, 400 μlo f
rmOPN (200 μg/ml in PBS) was added and the mix-
ture was incubated for 72 hours at 37°C in a shaking
water bath. After incubation, the resin was removed
by centrifuging the mixture for 5 minutes at 500 × g
and collecting the supernatant. To further purify the
thrombin-cleaved OPN (T-OPN), the supernatant was
centrifuged twice at 10,000 × g for 5 minutes. After
each centrifugation, the supernatant was collected and
any remaining thrombin-agarose resin was discarded.
The same procedure was performed for preparation of
the vehicle, but 400 μl of PBS was added to the 10×
cleavage buffer and thrombin-agarose resin mixture
instead of 400 μl of rmOPN. The efficiency of the
thrombin cleavage is shown in the Western blots in
Figure 1.
Peptides
OPN-derived peptides from the sequences on the N-
terminal and C-terminal sides of the thrombin cleavage
site in the OPN protein were custom synthesized by
New England Peptide (Gardener, MA, USA). The pep-
tide from the N-terminal fragment was synthesized from
OPN amino acids 134 to 153 (N134-153), and the
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rmOPN, N134–153 and C154–198 were dissolved in PBS
and were injected into the left lateral ventricle immediately
before HI in PND5 mice. Control mice received injections
of vehicle alone (PBS). The pups were anesthetized with iso-
flurane (5.0% for induction and 1.5% to 3.0% for mainten-
ance), and 2 μl of drug or vehicle was injected using a
syringe attached to a microinjection pump (CMA Microdi-
alysis, Stockholm, Sweden) at a speed of 1.25 μl/min at a
depth of 1.9 mm from the skull skin surface. Table 1 shows
the doses and concentrations of rmOPN, N134–153 and
C154–198 used for intracerebroventricular (ICV) injections.
Intranasal administration of recombinant mouse
osteopontin and osteopontin-derived peptides
For all intranasal administrations, PND5 pups were laid
on their backs and held gently to prevent them from
moving during administration. One hour before intranasal
administration, the pups were pretreated with hyaluroni-
dase to improve the delivery of protein/peptide (total of
60 U in 6 μl, H-4272; Sigma-Aldrich, Gothenburg,
Sweden) [18]. The hyaluronidase was administered by ap-
plying a single 1.5-μld r o p( 1 0U / μl) to each nostril of the
pup, and, when the drop had been inhaled by the pup, a
second drop was added to each nostril.
Immediately before and after the pups were put under
10% oxygen (hypoxia), rmOPN, T-OPN, N134–153 or
vehicle was administered to the pups by applying a 1.5-
μl drop to each nostril. After the drop was inhaled by
the pup, a second drop was administered. The doses and
concentrations used in each treatment are shown in
Table 1.
The rmOPN protein and N134–153 peptide used for
intranasal administration were both reconstituted in
PBS. Thus, PBS served as the vehicle for both treat-
ments, and the results from the vehicle treatment in
both groups were pooled when the data were analyzed.
For T-OPN, PBS treated with the Thrombin CleanCleave
Kit was used as the vehicle.
Immunohistochemical staining
At 6 hours, 3 days or 7 days after HI-induced injury, the
mice were deeply anesthetized and perfused intracardi-
ally with saline and 6% buffered formaldehyde (Histofix;
Histolab, Gothenburg, Sweden). Their brains were dis-
sected out, paraffin-embedded and cut into 10-μm cor-
onal sections.
Antigen recovery was performed by heating the sec-
tions in 10 mM boiling sodium citrate buffer (pH 6.0)
for 10 minutes. Nonspecific binding was blocked for 30
minutes with 4% horse, goat or donkey serum (depend-
ing on the species used to raise the secondary antibody)
in PBS. The primary antibodies used were mouse anti-
MAP2 (1:2,000 dilution, microtubule-associated protein
2 antibody; Sigma-Aldrich), mouse anti-MBP (1:10,000 di-
lution, myelin basic protein, SMI 94; BioLegend, Dedham,
MA, USA) and rabbit anti-OPN (1:400; Immuno-Biological
L a b o r a t o r i e s ,G u n m a ,J a p a n ) .A f t e ri n c u b a t i n gt h eb r a i n
sections with the primary antibodies overnight at 4°C,
the appropriate biotinylated secondary antibodies (1:250;
all from Vector Laboratories, Burlingame, CA, USA) were
Figure 1 A representative Western blot shows the efficiency of
thrombin cleavage of recombinant mouse osteopontin. (A)
Molecular weight marker. (B) Untreated recombinant mouse osteopontin
(rmOPN) protein. (C) Thrombin-treated rmOPN protein. (D) Cleavage
fragments of thrombin-treated OPN.
Table 1 Doses used for drug administration
a
Intracerebroventricular administration Intranasal administration
rmOPN N134–153 C154–198 rmOPN T-OPN N134–153
Dose (μg/pup) 0.05 0.2 0.5 1.2 1.2 30
Concentration (μg/μl) 0.025 0.1 0.25 0.2 0.2 5
Volume (μl) 22 2 6 6 6
aC154–198, Osteopontin C-terminal residues 154 to 198; N134–153, Osteopontin N-terminal residues 134 to 153; rmOPN, Recombinant mouse osteopontin; T-OPN,
Thrombin-cleaved osteopontin.
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was performed using the Vectastain ABC Elite Kit (Vector
Laboratories) with 0.5 mg/ml 3,3′-diaminobenzidine en-
hanced with 15 mg/ml ammonium nickel sulfate, 2 mg/ml
β-D-glucose, 0.4 mg/ml ammonium chloride and 0.01
mg/ml β-glucose oxidase (all from Sigma-Aldrich).
For immunofluorescent staining, sections were incu-
bated with the following primary antibodies: rabbit anti-
OPN (1:400; Immuno-Biological Laboratories), mouse
anti-Iba-1 (1:750; EMD Millipore, Billerica, MA, USA),
mouse anti-GFAP (1:50; Sigma-Aldrich) and mouse anti-
NeuN (1:50; EMD Millipore) at 4°C overnight. After pri-
mary antibody incubation, the sections were incubated
with appropriate combinations of secondary antibodies,
including donkey anti-rabbit Alexa Fluor 488 (1:500),
donkey anti-rabbit Alexa Fluor 594 (1:500) and donkey
anti-mouse Alexa Fluor 488 (1:500; all from Molecular
Probes, Leiden, the Netherlands), for 1 hour at room
temperature, and a coverslip was mounted using ProLong
Gold antifade reagent with 4′,6-diamidino-2-phenylindole
(DAPI, Life Technologies, Carlsbad, CA, USA).
Assessment of white-matter/gray-matter injury
The extent of white-matter/gray-matter injury was eval-
uated at 7 days after HI-induced injury. For evaluation
of brain injury, every 50th section throughout the brain,
or a representative section from the hippocampal level,
was stained for the presence of microtubule-associated
protein 2 (MAP2) or myelin basic protein (MBP).
Gray-matter injury was quantified by measuring the total
area of MAP2-positive staining at 4× magnification using
the Micro Image version 4.0 software package (Micro-
Macro AB, Gothenburg, Sweden). White-matter injury was
quantified by measuring the area of MBP-positive stain-
ing [19,20]. Tissue loss was calculated by subtracting
the amount of staining in the ipsilateral hemisphere
from that of the contralateral hemisphere.
RT-PCR
OPN expression in the brain at 6 hours, 24 hours and 7
days after HI-induced injury at PND5, as well as in unin-
jured control mice, was analyzed by RT-PCR.
For PCR, the mice were deeply anesthetized and per-
fused intracardially with saline at 6 hours, 24 hours or 7
days post-HI, and the brains were rapidly dissected out,
divided into ipsilateral and contralateral hemispheres,
snap-frozen and stored at −80°C until use. Both the ipsi-
lateral and contralateral hemispheres from HI-injured
mice were used, and only the left hemispheres from un-
injured control mice were used.
A QIAzol Lysis Reagent homogenizer (Qiagen, Solna,
Sweden) was used to homogenize the brain tissue, and
total RNA was extracted using the RNeasy Lipid Tissue
Mini Kit (Qiagen). RNA levels were measured on a
spectrophotometer at 260-nm absorbance. The Quanti-
Tect Reverse Transcription Kit (Qiagen) was used to
synthesize cDNA according to the manufacturer’s instruc-
tions. The primers used were OPN (spp1) (QT00157724)
and 18S ribosomal RNA (QT01036875) (both from
Qiagen).
Each reaction was run in duplicate, and the amplifica-
tion protocol was run on a LightCycler 480 apparatus
(Roche, Stockholm, Sweden). Melting curves were ana-
lyzed to ensure that only one PCR product had been
produced. A standard curve using increasing concentra-
tions of cDNA was generated for quantification and for
estimating amplification efficiency. The amplification tran-
scripts were quantified with the relative standard curve
and normalized to the 18S ribosomal RNA reference gene.
Western blot analysis
Total protein from brain homogenate was analyzed by
Western blotting to determine the endogenous expression
of OPN in the brain during normal development. Mice
were killed by decapitation at PND3, PND9, PND21 or
PND60, and their brains were rapidly dissected out, di-
vided into two hemispheres and snap-frozen. The brains
were homogenized by sonication in ice-cold, RNase-free
PBS buffer containing 2% protease inhibitor cocktail
(P8340; Sigma-Aldrich) and 10 mM ethylenediaminetetra-
acetic acid and stored at −80°C until use.
Samples of brain homogenate were denatured in gel-
loading buffer at 70°C for 10 minutes and loaded onto a
4–12% Tris-Bis gel (Life Technologies). Proteins were
transferred to a nitrocellulose membrane (0.2 μm, Optitran;
Schleicher & Schuell, Dassel, Germany). After blocking
with 30 mmol/L Tris-HCl (pH 7.5), 100 mmol/L NaCl
and 0.1% Tween 20 containing 5% fat-free milk powder
for 1 hour at room temperature, the membranes were
incubated with polyclonal anti-OPN primary antibody
(1:2,000, ab8448; Abcam, Cambridge, UK) for 1 hour at
room temperature, followed by incubation with goat
anti-rabbit horseradish peroxidase–labeled secondary
antibody (1:5,000; Vector Laboratories) for 1 hour at room
temperature. SuperSignal Western Dura chemilumines-
cent substrate (Thermo Scientific, Waltham, MA, USA)
and a LAS-1000 cooled charge-coupled device camera
(Fujifilm, Tokyo, Japan) were used for visualization, and
Image Gauge software (Fujifilm) was used for quantifica-
tion of immunoreactive bands.
Statistics
The SPSS software package v19.0 (SPSS, Chicago, IL,
USA) was used for all analyses. Data were expressed as
mean ± standard deviation (SD). Comparisons between
groups were performed using Student’s t-test, and data
with unequal variance were compared with the Mann–
Whitney U test. Analysis of variance followed by the least
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son of data from more than two groups. P-values <0.05
were considered statistically significant.
Results
Endogenous osteopontin expression in the neonatal
mouse brain
We first examined the endogenous expression of OPN
in wild-type mice during normal development. Western
blot analysis of total protein in whole-brain homogenate
from normal uninjured mice at PND3, PND9, PND21
and PND60 showed that OPN expression in the brain
decreased with age. At PND9, an age that is comparable
to that of human near-term infants, the expression of
OPN in the brain was already starting to decrease com-
pared to PND3 mice (Figures 2A and B).
To evaluate whether the expression of OPN was regu-
lated after HI-induced injury in PND5 mice, brains were
harvested at 6 hours, 24 hours or 7 days postinjury and
total RNA was analyzed by RT-PCR. OPN mRNA ex-
pression was significantly increased in the brain hemi-
sphere ipsilateral to the ligated carotid artery compared
to the contralateral hemisphere and compared to unin-
jured mice at 6 hours, 24 hours and 7 days after HI insult
(Figure 2C). There was no difference in the contralateral
hemisphere of the treated animals compared to those that
had not been exposed to HI (Figure 2C).
To confirm the expression of OPN protein in the
brain after HI, immunohistochemistry using an anti-
OPN antibody was performed on paraffin-embedded
brain sections from 6 hours or 3 days after HI-induced
injury (Figure 3). At 6 hours after HI, OPN-positive
staining in both the contralateral (Figures 3A and C)
and the ipsilateral (Figures 3B and D) hemispheres was
observed in the periventricular areas (Figures 3C and D),
the hippocampus, the white matter, the thalamus and the
meninges. Significantly greater staining was seen in the ip-
silateral hemisphere (Figures 3B,D to H) compared to the
contralateral hemisphere (Figures 3A and C). At 3 days
post-HI, the OPN-positive staining was located mainly in
the ipsilateral subcortical white matter (Figures 3I and J),
thalamus (Figures 3I and K), hippocampus (Figure 3I)
and the part of the cortex adjacent to the subcortical
white matter (Figures 3I,L and M). Interestingly, we no-
ticed that OPN-positive cells showed a perinuclear dis-
tribution of the OPN protein in the cells (Figures 3N,
O and P) that was similar to the distribution of intra-
cellular OPN seen in a previous study [21].
Immunofluorescent double labeling showed that the
majority of the OPN-positive cells were double-labeled
with the microglial marker Iba-1 (Figures 4A to F), none
colocalized with the neuronal marker NeuN (Figures 4G
to I) and only a few colocalized with the astrocyte marker
glial fibrillary acidic protein (GFAP, data not shown).
Effect of T-OPN-, rmOPN- and OPN-derived peptides on
HI-induced preterm brain injury in postnatal day 5 mice
Intranasal administration is a noninvasive method of
drug delivery that can bypass the blood–brain barrier
and provide therapeutic substances with direct access to
the central nervous system (CNS), and this route of ad-
ministration of drugs and cells is also efficient in the im-
mature brain injury rodent models [22,23]. Especially,
intranasal delivery has been shown to be an efficient way
of delivering rmOPN protein and peptides to the CNS
Figure 2 Endogenous expression of osteopontin in the brain in
normal and hypoxia-ischemia-injured mice. In uninjured mice,
the expression of endogenous osteopontin (OPN) during development
was analyzed by Western blotting using the whole-brain homogenates
at postnatal day 3 (P3), P9, P21 and P60. (A) A representative Western
blot. (B) The quantification of the Western blot analysis by measuring
the density of the immunoreactive bands (n =3 ) .(C) The mRNA
expression of endogenous OPN in the left hemisphere of uninjured
control mice (Cont) and the contralateral (Contra) and ipsilateral (Ipsi)
hemispheres after hypoxia-ischemia (HI) injury (n = 6 to 8). The data
are presented as the ratios between OPN and reference gene (18S)
mRNA expression. No changes in the 18S mRNA expression were
observed in the brain after HI-induced injury. Data presented are the
mean ± SD. *P <0 . 0 5 ;* * P < 0.01; ***P <0 . 0 0 1 .
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Osteopontin (OPN)-positive staining (arrows in A and B) in the contralateral hemisphere (A and C) and ipsilateral hemisphere (B and D)a t6
hours after hypoxia-ischemia (HI)-induced injury. The positive staining was seen in the hippocampus, the lateral ventricle area (C and D), the
thalamus and the meninges. (C) and (D) Enlarged images of the periventricular areas shown within the boxed areas in (A) and (B), (E) through (H)
Higher-magnification images of OPN-positive cells from the periventricular region (E and F) and white matter (G and H) of the ipsilateral hemisphere.
(I) through (M) At 3 days after HI, OPN-positive immunostaining was found mainly in the subcortical white matter area (arrows in I) in the ipsilateral
hemisphere. (J) through (M) Higher-magnification images of OPN-positive cells in the ipsilateral hemisphere white matter (J),t h a l a m u s(K) and cortex
(L and M). (N) through (P) The perinuclear expression of OPN (arrows) in the brain after HI. Green: OPN staining. Blue: nuclear staining. Bars in
D =5 0μm; bars in E through H, J through M,a n dP =1 0μm; bars in N and O =1 0μm.
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persistence in the brain through intranasal administra-
tion [6], and rmOPN and T-OPN have been shown to
provide efficient protection against ischemic brain injury
in a mouse model of stroke [6]. Therefore, we sought to
determine if rmOPN and T-OPN also confer neuropro-
tection in a preterm brain injury model.
T-OPN was administered intranasally immediately be-
fore and after hypoxia in an HI-induced preterm brain
injury model in PND5 mice. The efficiency of thrombin
cleavage of rmOPN was analyzed by Western blotting,
which showed that all of the rmOPN had been success-
fully cleaved by thrombin (Figure 1). At 7 days after in-
duction of HI, the brain injury in the gray matter and
white matter was evaluated by immunostaining of
MAP2 and MBP, respectively. However, no difference
was seen between the T-OPN-treated group and the
vehicle-treated group (Figures 5A and B) in terms of ei-
ther gray-matter (Figure 5A) or white-matter (Figure 5B)
injury. Similarly, we did not observe any significant dif-
ferences in gray- or white-matter injury after intranasal
rmOPN treatment (Figures 5C and D).
To evaluate the possibility that the lack of effect was
due to technical issues with the intranasal administra-
tion, we next administered rmOPN using ICV injection.
ICV injection is a well-accepted method for the delivery
of drugs directly to the CNS in rodent models that we
have successfully used in our previous studies [24,25],
and ICV administration of exogenous OPN has been
shown to protect both adult mice [7] and neonatal rats
[11] from ischemic brain injury. When we compared the
tissue loss in gray matter and white matter between the
rmOPN-treated animals and the vehicle-treated animals,
we detected no difference between the rmOPN-treated
Figure 4 Osteopontin expression in microglia, astrocytes and neurons in the neonatal mouse brain after hypoxia-ischemia-induced
injury. Representative pictures of immunofluorescent double staining show the costaining of osteopontin (OPN) (red in A, B and F) with Iba-1
(green in C, D and F) and with NeuN (green in H and I) in the periventricular area in the ipsilateral hemisphere at 6 hours after HI. Arrows in (F)
indicate cells that coexpress OPN and Iba-1. DAPI (blue in B, D, E-I).
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(Figure 5E) or the white matter (Figure 5F), and these
findings corresponded well to the results from the intra-
nasal administration (Figure 5C, D).
To further evaluate the effect of rmOPN on HI-induced
preterm brain injury, OPN
−/− animals were used. The lack
of protective effect of rmOPN was further confirmed by
ICV administration of rmOPN or vehicle immediately be-
fore hypoxia in OPN
−/− mice (data not shown). Further-
more, the volume of HI-induced gray-matter (Figure 6A)
and white-matter (Figure 6B) tissue loss was not different
comparing OPN
−/− and wild-type mice, and this suggests
that endogenous OPN does not affect development of
brain injury in the preterm brain.
In an adult mouse model of stroke, intranasal adminis-
tration of the OPN-derived N134–153 peptide provided
significant neuroprotection [6]. To examine whether in-
tranasal administration of this short peptide could also
provide neuroprotection in our HI-induced preterm
brain injury model, we administered the OPN-derived
N134–153 peptide, which contains the RGD motif, to
neonatal mice immediately before and after hypoxia at
PND5. Surprisingly, intranasal administration of the
N134–153 peptide resulted in exacerbated injury with
Figure 6 The effect of osteopontin deficiency on preterm brain
injury. Bar graphs show the total tissue volume loss (%) in the gray
matter (A) and white matter (B) of wild-type (WT) and osteopontin
(OPN)-deficient (OPN
−/−) mice at 7 days after hypoxia-ischemia-induced
brain injury. WT: n =1 3 ;O P N
−/−: n = 15. Data presented are mean ± SD.
Figure 5 The effect of thrombin-cleaved osteopontin and recombinant mouse osteopontin on preterm brain injury. Bar graphs show
the total tissue volume loss (%) in the gray matter (A, C and E) and white matter (B, D and F) of mice given intranasal thrombin-cleaved osteopontin
(T-OPN) (A and B), intranasal recombinant mouse OPN (rmOPN) (C and D) and intracerebroventricular (ICV) rmOPN (E and F) at 7 days after
hypoxia-ischemia (HI)-induced injury. Intranasal administration: vehicle (Veh), n = 20; T-OPN, n = 14; rmOPN, n = 17. ICV administration: vehicle
(Veh), n = 31; rmOPN, n = 27. Data presented are the mean ± SD.
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of white matter, compared to vehicle at 7 days after HI
(Figures 7A and B). To make sure that the peptide really
had this effect in the brain and that this unexpected in-
crease in injury severity was not an experimental artefact
attributable to the intranasal delivery, we also adminis-
tered the peptide using ICV administration. We found
that ICV administration of N134–153 worsened the HI-
induced gray-matter brain injury in the PND5 mouse
model (Figure 7C) but had no effect on the white-matter
injury (Figure 7D).
With these unexpected results showing increased
brain injury with the N134–153 peptide, we used a sec-
ond peptide, the C154–198 peptide, generated from the
sequence at the C-terminal fragment of the OPN protein
after thrombin cleavage, which has also been shown to
be protective in an adult stroke model [6]. Because we
had shown that the intranasal administration and the
“traditional” ICV delivery methods gave similar results
for rmOPN and N134–153 in our model, C154–198 was
administered only by the ICV route. Again, mice treated
with C154–198 displayed increased injury in the gray
matter (Figure 8A), as well as significantly increased tis-
sue loss in the white matter, compared to the vehicle-
treated control group (Figure 8B).
Discussion
In this study, we evaluated the effect of the exogenous
OPN protein as well as OPN-derived peptides on the
outcome of HI-induced preterm brain injury in mice.
We found that the OPN-derived N134–153 and C154–
198 peptides exacerbated the brain injury, but neither
full-length rmOPN nor T-OPN had any effect on HI-
induced preterm brain injury. This lack of effect of full-
length OPN was seen after administration of rmOPN to
both wild-type mice and OPN
−/− mice subjected to HI
and also in OPN
−/− mice subjected to HI alone. We also
found that intranasal delivery of N134–153 to PND5
mice before HI had an effect on brain injury comparable
to ICV administration, which suggests that intranasal ad-
ministration is an efficient way of delivering drugs to the
CNS in mouse models of HI-induced preterm brain
injury.
Figure 7 The effect of the osteopontin-derived N134–153 peptide on preterm brain injury. Bar graphs show the total tissue volume loss
(%) in the gray matter (A and C) and white matter (B and D) in mice that received intranasally administered osteopontin amino acids 134 to 153
(N134–153) (A and B) and intracerebroventricularly (ICV) administered N134–153 (C and D) at 7 days after hypoxia-ischemia (HI)-induced injury.
Intranasal administration: vehicle (Veh), n = 20; N134–153, n = 16. ICV administration: vehicle (Veh), n = 31; N134–153, n = 15. Data presented are
the mean ± SD. *P < 0.05. (E) Representative immunohistochemical stains of microtubule-associated protein 2 (MAP-2) (gray matter) and myelin
basic protein (MBP) (white matter) showing injury (arrows) in brain sections of the vehicle-treated (Veh) and N134–153-treated mice at 7 days after
HI injury in postnatal day 5 mice.
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http://www.jneuroinflammation.com/content/11/1/197There is evidence that OPN plays an important role in
the pathogenesis of adult white-matter injury diseases
such as multiple sclerosis, as well as in animal models of
experimental autoimmune encephalomyelitis (EAE). In-
creased OPN expression is frequently found in the spinal
cord in patients with multiple sclerosis [26-28] and at
the injury site in animal models of white-matter disease
[29,30]. OPN
−/− mice are resistant to progressive EAE
[26,31], and OPN is upregulated during in vivo demye-
lination and remyelination and enhances myelin forma-
tion in vitro [29]. Taken together, these findings suggest
that OPN might play a detrimental role in multiple
sclerosis, at least in the inflammatory phase.
In some other ischemic brain injury cases, such as in
the adult rodent models, OPN
−/− mice exhibited un-
altered infarction volume [7,32] but greatly increased
retrograde degeneration in the thalamus in a stroke
model [32]. Administration of rmOPN protein [7] or
administration of a short peptide containing the RGD
motif resulted in significantly reduced infarction size in
the brain [6]. However, OPN enhanced endogenous re-
pair and was protective in mouse and rat models of HI-
induced neonatal brain injury [10,11].
Although we found increased expression of OPN in
the microglia after HI in the mouse preterm brain injury
model, which is in agreement with previous findings
[8,11], we did not find any protective effect of rmOPN
against HI-induced preterm brain injury. This lack of ef-
fect was further confirmed using OPN
−/− mice. These
results differ from previous studies in which researchers
showed that rmOPN protects PND7 rats from HI-
induced brain injury [11] and that OPN
−/− mice sustain
more severe injury in a PND9 HI brain injury mouse
model [10]. These models correspond to the brain injury
seen in near-term human infants. A power analysis was
performed to make sure that the differing results in the
present study compared to previous studies were not
related to an issue of using an insufficient number of
animals.
Inflammation stimulates both pro- and anti-inflammatory
processes, and the balance of these processes can be
either beneficial or harmful depending on what other
inputs the cell is receiving. It is known that full-term
infants with HIE and animal models of “near-term”
brain injury typically exhibit cortical and mixed deep
gray-matter injury [33], whereas diffuse white-matter
injury, together with gray-matter abnormalities, are the
most common types of cerebral abnormalities associ-
ated with prematurity [2,34-36]. Apart from differences
in brain injury pathology, previous studies have indi-
cated that the cell death mechanisms in brain injury
differ at different developmental stages [37,38], and it
has been found that the expression of some integrin
units varies during different developmental stages. For
example, the migratory and proliferating precursor oli-
godendrocytes express αvβ1,b u tp o s t m i g r a t o r ya n d
postmitotic differentiated oligodendrocytes upregulate
αvβ5 and αvβ1 disappears. These integrin subunits have
a functional role in regulating the proliferation and dif-
ferentiation in oligodendrocyte progenitor cells [39]
and in myelination [40-42], and they affect the sensitiv-
ity of oligodendrocytes to the survival effect of growth
factors [43]. It is known that pre-OLs, which are vul-
nerable cell types in preterm brain injury, are expressed
most abundantly in PND2 to PND5 rodents and quickly
decline in older rodents [12]. By PND7, extensive oligo-
dendrocyte maturation occurs in both mice and rats and
coincides with the onset of early myelination [44].
Integrin subunits, including the αv and β2 integrin sub-
units that act as OPN receptors, are important regula-
tors during the development of oligodendrocytes [14],
cortical neurons [45-47], postnatal synaptogenesis [48]
and synaptic function [49]. Moreover, the distribution of
integrin subunits is different between the white and gray
matter at an early postnatal age [50]. Thus, it is possible
that the different integrin expression levels at different
oligodendrocyte/neuronal development stages control the
delicate binding between the integrins and their ligands
and lead to different outcomes. These various aspects
might partly explain the different effects of OPN on brain
injury in our preterm brain injury model using PND5
mice compared to the effects of OPN in the neonatal
near-term brain injury model using PND9 mice [10] and
PND7 rats [11] and in the adult stroke model [6,7].
A molecular dissection of OPN [4,51-54] has defined
two functionally distinct domains of the OPN protein.
The N-terminal fragment of T-OPN contains the RGD
tripeptide that interacts with several αv-containing integ-
rins [3,55-57]. This interaction mediates the antiapopto-
tic effects of OPN through several pathways, including
inhibition of inducible nitric oxide synthase activity
[58,59]. The C-terminal fragment of T-OPN interacts
with CD44 receptors and promotes Th17-dependent
Figure 8 The effect of the C154–198 peptide on preterm brain
injury. Bar graphs show the total tissue volume loss (%) in the gray
matter (A) and white matter (B) of the intracerebroventricularly (ICV)
treated C154–198 peptide mouse group at 7 days after hypoxia-ischemia
(HI)-induced injury. Vehicle (Veh), n = 31; C154–198, n = 23. Data
presented are the mean ± SD. *P < 0.05.
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injury [51,54,60,61]. These results indicate that the N-
and C-terminal fragments of T-OPN might have differ-
ent effects on the progression of preterm brain injury. In
the present study, both the RGD-containing N134–153
peptide and the C154–198 peptide worsened brain in-
jury in the HI-induced preterm brain injury model. The
difference in effects of the N134–153 and C154–198
peptides is that the N134–153 peptide mainly affected
the gray matter, whereas the C154–198 peptide had an
effect on both the gray and white matter. One explan-
ation for this distinction is that the two peptides interact
with different receptors using different binding sites.
The N134–153 peptide contains the RGD motif that is
known to bind specific integrin receptors, such as αvβ1,
αvβ3, αvβ5, αvβ6, α8β1 and α5β1, whereas the C154–198
peptide fragment does not contain this RGD motif and
binds to other receptors, such as CD44. Our results indi-
cate that binding sites from the N- and C-terminal frag-
ments of OPN after thrombin cleavage, rather than the
full-length OPN protein, might be used to further ex-
plore possible therapeutic strategies for preterm brain
injury. However, the exact site of action and the under-
lying mechanisms of the peptide in preterm brain injury
need to be further explored.
Intranasal delivery of high-molecular-weight biologics
such as proteins, gene vectors and stem cells is a poten-
tially useful strategy to treat a variety of diseases and dis-
orders of the CNS, including stroke, and is an easy and
noninvasive method of drug delivery [62] that has shown
promise in several clinical trials [63]. The rationale for in-
tranasal delivery stems from the unique anatomy of the ol-
factory region of the nasal cavity. Specialized olfactory
receptor cells in this region are the major “open windows”
to the CNS and allow drugs to bypass the blood–brain
barrier. Accumulating evidence indicates that a wide range
of substances, including high-molecular-weight sub-
stances, water-soluble molecules, nucleic acids, viruses
and even whole cells can enter the CNS of many species,
including humans, after intranasal administration [64].
Intranasal administration can deliver OPN to the area of
the brain that is rendered ischemic by middle cerebral ar-
tery occlusion (MCAO), and intranasal administration of
T-OPN protects the adult mouse brain from MCAO in-
jury [6]. It has previously been shown that intranasal ad-
ministration is also a valid method for delivery of cells to
the CNS in newborn mice [65]. In the present study, we
found that intranasal delivery of N134–153 had the same
effect as ICV administration. These results show for the
first time that intranasal delivery can serve as an efficient
noninvasive method for drug delivery to the preterm brain
and suggest that intranasal delivery could be explored as a
simple and efficient method of delivering drugs to the
CNS in preterm infants with brain injury.
Conclusions
We found that OPN expression increased after induction
of HI in the preterm brain injury model. Administration
of rmOPN and T-OPN did not confer any protective
effect, but both the OPN-derived RGD-containing N134–
153 and the C154–198 peptides increased the severity of
the brain injury. This indicates that the neuroprotective
effects of OPN are age-dependent and that, in contrast to
the more mature brain, OPN-derived peptides potentiate
injury in PND5 mice.
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